secwatch.observer — SEC 8-K summary
======================================

Issuer:     XOMA Royalty Corp (XOMA)
CIK:        0000791908
Form:       8-K
Filed at:   2024-04-03T23:59:59+00:00
Accession:  0001193125-24-085545
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

XOMA completes acquisition of Kinnate Biopharma for $2.5879 per share plus CVRs
-------------------------------------------------------------------------------

- XOMA purchased ~81% of Kinnate shares via tender offer at $2.5879/share plus one CVR per share.
- Merger closed under DGCL Section 251(h); remaining shares converted to same consideration.
- CVRs entitle holders to potential payments from future disposition of Kinnate's products within one year, up to five years.
- Total of 38,258,681 shares tendered; all conditions satisfied for merger.
- XOMA expects to realize value from Kinnate's pipeline; CVR agreement filed as exhibit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/791908/000119312524085545/0001193125-24-085545-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/791908/000119312524085545/d793644d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-085545

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer